Collegium Pharmaceutical (NASDAQ:COLL) Rating Lowered to Buy at StockNews.com
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Saturday. A number of other analysts also recently weighed in on the stock. Needham & Company LLC reissued a “buy” rating and set a […]
